Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) for Meningococcal Conjugate Vaccines in HIV-Infected Persons

The evidence type for use of meningococcal conjugate vaccine in HIV-infected persons aged ≥2 months was determined to be type 3 (low level of evidence). After reviewing the result of the GRADE analysis and other data demonstrating increased risk of meningococcal disease among HIV-infected persons, the Advisory Committee on Immunization Practices (ACIP) recommended that HIV-infected persons aged ≥2 months be routinely vaccinated with a MenACWY vaccine to prevent meningococcal disease (recommendation Category A). The full recommendations for the use of MenACWY vaccines in HIV-infected persons aged ≥2 months are available on the ACIP website.